{
    "title": "111_s1158",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``SMA Treatment Acceleration Act of \n2009''.\n\nSEC. 2. CLINICAL TRIALS NETWORK FOR SPINAL MUSCULAR ATROPHY.\n\n    Part B of title IV of the Public Health Service Act is amended by \nadding at the end the following new section:\n\n``SEC. 409J. CLINICAL TRIALS NETWORK FOR SPINAL MUSCULAR ATROPHY.\n\n    ``(a) Clinical Trials Network.--The Director of NIH, in \ncoordination with the Directors of the National Institute of \nNeurological Disorders and Stroke, the National Institute of Child \nHealth and Human Development, and such other Institutes and Centers as \nspecified by the Director shall provide for the upgrading and \nunification of spinal muscular atrophy clinical trial sites and the \nrecruitment of new investigators and sites to establish a national \nclinical trials network for spinal muscular atrophy. The Director of \nNIH shall ensure that such network--\n            ``(1) conducts coordinated, multisite, clinical trials of \n        therapies and clinical approaches to the treatment of spinal \n        muscular atrophy; and\n            ``(2) rapidly and efficiently disseminates scientific \n        findings to the field.\n    ``(b) Data Coordinating Center.--The Director of NIH, in \ncoordination with the Commissioner of Food and Drugs and the Directors \nof the National Institute of Neurological Disorders and Stroke, the \nNational Institute of Child Health and Human Development, and such \nother Institutes and Centers as specified by the Director, shall \nestablish a data coordinating center with respect to spinal muscular \natrophy to--\n            ``(1) provide expert assistance in the design, conduct, \n        data analysis, data management, and data warehousing of \n        collaborative clinical and descriptive research projects;\n            ``(2) organize and conduct multi-site monitoring \n        activities;\n            ``(3) provide regular reports to the National Institute of \n        Neurological Disorders and Stroke, the National Institute of \n        Child Health and Human Development, such other Institutes and \n        Centers as specified by the Director, and the Food and Drug \n        Administration on enrollment and the allocation of resources; \n        and\n            ``(4) conduct such other activities as are deemed necessary \n        by the Secretary.\n    ``(c) Pre-Clinical Activities.--The Director of NIH, in \ncoordination with the Directors of the National Institute of \nNeurological Disorders and Stroke and the National Institute of Child \nHealth and Human Development, shall expand and intensify programs of \nsuch Institutes with respect to pre-clinical translation research \nrelated to spinal muscular atrophy.''.\n\nSEC. 3. NATIONAL PATIENT REGISTRY.\n\n    Part P of title III of the Public Health Service Act is amended by \nadding at the end the following new section:\n\n``SEC. 399S. NATIONAL SPINAL MUSCULAR ATROPHY PATIENT REGISTRY.\n\n    ``(a) In General.--The Secretary, acting through the Director of \nthe Centers for Disease Control and Prevention and in coordination with \nthe Director of the NIH, shall enhance and provide ongoing support to a \nspinal muscular atrophy patient registry to provide for expanded \nepidemiological research towards improving awareness, management, \ntreatment, and prevention of spinal muscular atrophy.\n    ``(b) Longitudinal Data.--In carrying out subsection (a), the \nSecretary shall ensure the collection and analysis of longitudinal data \nrelated to individuals of all ages with spinal muscular atrophy, \nincluding infants, young children, adolescents, and adults of all \nages.''.\n\nSEC. 4. INTERAGENCY SPINAL MUSCULAR ATROPHY RESEARCH COORDINATING \n              COMMITTEE.\n\n    Part B of title IV of the Public Health Service Act, as amended by \nsection 2, is further amended by adding at the end the following new \nsection:\n\n``SEC. 409K. INTERAGENCY SPINAL MUSCULAR ATROPHY RESEARCH COORDINATING \n              COMMITTEE.\n\n    ``(a) Establishment.--Not later than 6 months after the date of the \nenactment of this section, the Secretary shall establish a committee, \nto be known as the Interagency Spinal Muscular Atrophy Research \nCoordinating Committee (in this section referred to as the \n`Committee').\n    ``(b) Duties.--The Committee shall--\n            ``(1) share and coordinate information on existing research \n        activities, and make recommendations to the National Institutes \n        of Health and other Federal agencies regarding how to improve \n        existing research programs, that are related to spinal muscular \n        atrophy research and other related neurological diseases and \n        disorders;\n            ``(2) develop a comprehensive strategy related to spinal \n        muscular atrophy research and other related neurological \n        diseases and disorders and advise the National Institutes of \n        Health and other Federal agencies, expanding proposals for \n        collaborative, multidisciplinary research, including proposals \n        for Common Fund research described in section 402(b)(7) and \n        other proposals that involve collaboration between 2 or more \n        national research institutes or national centers;\n            ``(3) provide annual reports to the Secretary regarding the \n        National Institutes of Health and other Federal agencies' \n        collaborative multidisciplinary research efforts to support \n        spinal muscular atrophy, including the Spinal Muscular Atrophy \n        Project at the National Institute of Neurological Disorders and \n        Stroke, the ongoing and future research needs to advance \n        therapies for spinal muscular atrophy, and recommendations on \n        how to strengthen the collaboration of research activities by \n        the institutes and agencies to improve the results;\n            ``(4) develop a summary of advances in research related to \n        spinal muscular atrophy research and other related neurological \n        diseases and disorders research supported or conducted by \n        Federal agencies; and\n            ``(5) not later than 1 year after the date of the \n        establishment of the Committee, make recommendations to the \n        Secretary--\n                    ``(A) regarding any appropriate changes to research \n                activities, including recommendations to improve the \n                research portfolio of the National Institutes of Health \n                to ensure that scientifically-based strategic planning \n                is implemented in support of research priorities that \n                impact research activities related to spinal muscular \n                atrophy and other related neurological diseases and \n                disorders;\n                    ``(B) identifying barriers to the development of \n                new treatments and cures for spinal muscular atrophy \n                and other related neurological diseases and disorders;\n                    ``(C) regarding public participation in decisions \n                relating to spinal muscular atrophy research and other \n                related neurological diseases and disorders to increase \n                the involvement of patient advocacy and community \n                organizations representing a broad geographical area;\n                    ``(D) on how best to disseminate information on \n                spinal muscular atrophy progress; and\n                    ``(E) on how to expand partnerships between public \n                entities, including Federal agencies, and private \n                entities to expand collaborative, cross-cutting \n                research.\n    ``(c) Rule of Construction.--In carrying out the duties described \nin subsection (b) with respect to research on spinal muscular atrophy, \nnothing in this section shall be construed to restrict the Secretary \nfrom including other neurological or genetic disorders, as appropriate, \nin such research if doing so may advance research in spinal muscular \natrophy or other related neurological diseases and disorders.\n    ``(d) Membership.--\n            ``(1) In general.--The Committee shall be composed of the \n        following voting members:\n                    ``(A) Not more than 11 voting Federal \n                representatives as follows:\n                            ``(i) The Director of the Centers for \n                        Disease Control and Prevention.\n                            ``(ii) The Director of the National \n                        Institutes of Health and the directors of such \n                        national research institutes and national \n                        centers (which shall include the National \n                        Institute of Neurological Disorders and Stroke, \n                        the National Institute of Child Health and \n                        Human Development, and the National Center for \n                        Research Resources) as the Secretary determines \n                        appropriate.\n                            ``(iii) The Commissioner of Food and Drugs.\n                            ``(iv) The heads of such other agencies and \n                        advisory committees as the Secretary determines \n                        appropriate, including the Health Resources and \n                        Services Administration, the Agency for \n                        Healthcare Research and Quality, and the \n                        Advisory Committee on Heritable Disorders and \n                        Genetic Diseases in Newborns and Children.\n                            ``(v) Representatives of other Federal \n                        agencies that conduct or support neurological \n                        research, or provide support services and \n                        resources for individuals with spinal muscular \n                        atrophy, such as the Department of Education \n                        and the Social Security Administration.\n                    ``(B) 9 additional voting members appointed under \n                paragraph (2).\n            ``(2) Additional members.--The Committee shall include \n        additional voting members appointed by the Secretary as \n        follows:\n                    ``(A) 6 members shall be appointed from among \n                scientists, physicians, and other health professionals, \n                who--\n                            ``(i) are not officers or employees of the \n                        United States;\n                            ``(ii) represent multiple disciplines, \n                        including clinical, basic, and public health \n                        sciences;\n                            ``(iii) represent different geographical \n                        regions of the United States;\n                            ``(iv) are from practice settings, \n                        academia, or other research settings; and\n                            ``(v) are experienced in scientific peer \n                        review process.\n                    ``(B) 3 members shall be appointed from members of \n                the general public, who represent individuals with \n                spinal muscular atrophy.\n            ``(3) Nonvoting members.--The Committee shall include such \n        nonvoting members as the Secretary determines to be \n        appropriate.\n    ``(e) Chairperson.--The voting members of the Committee shall \nselect a chairperson from among the Federal members of the Committee \ndescribed in subsection (d)(1)(A). The selection of a chairperson may \nbe subject to the approval of the Secretary. The chairperson shall \nserve for a term of not to exceed 2 years, but may be re-elected as \nprovided for in the first sentence.\n    ``(f) Meetings.--The Committee shall meet at the call of the \nchairperson of the Committee or upon the request of the Secretary, but \nin no case less often than once each year.\n    ``(g) Review.--In 2012, and biennially thereafter, the Secretary \nshall review the necessity of the Committee.''.\n\nSEC. 5. EDUCATION AND AWARENESS ON SMA FOR HEALTH CARE PROFESSIONALS.\n\n    Part P of title III of the Public Health Service Act, as amended by \nsection 3, is further amended by adding at the end the following new \nsection:\n\n``SEC. 399T. INFORMATION AND EDUCATION ON SMA.\n\n    ``The Secretary shall establish and implement a program to provide \ninformation and education on spinal muscular atrophy to health \nprofessionals and the general public, including information and \neducation on advances in the screening, diagnosis, and treatment of \nspinal muscular atrophy and training and continuing education through \nprograms for scientists, physicians, medical students, and other health \nprofessionals who provide care for patients with spinal muscular \natrophy.''."
}